ERA4TB

COMBINE consortium invites you to an insightful webinar on Developing an in vivo Screening cascade to support Target Product Profiles for antibiotics! Don’t miss out! 🗓 Date: June 18th ⏰ Time: 15:00-16:30 CEST Register now! 🔗 https://lnkd.in/eqJ2jSTF #GlobalAMRChallenge #Antibiotics #DrugDevelopment

Stay Ahead with the Latest in AMR Accelerator! Dive into our newest newsletter for exciting updates on project wrap-ups, a spotlight on @IMI_ERA4TB, and exclusive expert webinars. Don't miss out—subscribe now and stay at the forefront of the Global AMR Challenge! 🔗 https://lnkd.in/eHtQemiT #GlobalAMRchallenge #Research #Healthcare #AMR GSK Uppsala University BIOCOM Interrelations GmbH Universidad Carlos III de Madrid Lygature European Vaccine Initiative (EVI) BioVersys AG Innovative Health Initiative (IHI)

📢 Two recent publications coming out of the UNITE4TB Consortium: 1. Developing biomarker assays to accelerate tuberculosis drug development: defining target product profiles Source: The Lancet, Microbe 👉 https://lnkd.in/e-zeujXQ "A big effort by the UNITE4TB biomarker team, which will aid future early- and late-stage drug trials and ultimately enable shorter, faster trials with biomarker endpoints," said contributing author and Consortium member, Morten Ruhwald, MD, PhD, Director of TB Programme at FIND. School of Medicine, University of St Andrews, Radboudumc, Ludwig-Maximilians-Universität München, LMU Klinikum München, FIND, German Center for Infection Research, Research Center Borstel, Johnson & Johnson, University of Oxford, Oxford University Clinical Research Unit. 2. Towards comprehensive clinical trials for new tuberculosis drug regimens: policy recommendations from a stakeholder analysis Source: BMJ Global Health, Volume 9, Issue 4 👉 https://lnkd.in/ekHiNyRg This study was carried out by the Centre Multidisciplinary Research in Health Science team at the Università degli Studi di Milano, part of the UNITE4TB Consortium. It discusses #tuberculosis (TB) research and development and the gaps that exist in terms of access to emerging #TB innovations in low- and middle-income countries with high TB burden. #PublicPrivatePartnership funded by the Innovative Medicines Initiative 2 (Innovative Health Initiative (IHI)). AMR Accelerator.

🌟 WHO Bacterial Priority Pathogens List 2024 is now live 🌟 👉 One of the aims of the update is to guide R&D for new, effective antibiotic therapies, aligning investment with clinical and public health needs. The list now categorizes 24 pathogens, spanning 15 families of antibiotic-resistant bacterial pathogens. Gram-negative bacterial pathogens: a continued critical priority in 2024. Critical-priority group includes: 🔸 Acinetobacter baumannii carbapenem-resistant (CRAB) 🔸 Various pathogens in the Enterobacterales order (CRE and 3GCRE) 🔸 Rifampicin-resistant (RR) Mycobacterium tuberculosis (please read the full report for more details) This update introduces a distinct ranking for 3GCRE, to highlight the need for targeted policies and interventions to address this emerging threat. High priority group includes: 🔸Pseudomonas aeruginosa carbapenem-resistant (CRPA) has been moved from “critical” to “high” due to a global decrease in resistance. However, investment in R&D for CRPA remains crucial! 🔸 Staphylococcus aureus methicillin-resistant (MRSA) remains a high priority in line with its high estimated burden. The WHO BPPL ranking reflects a notable increase in recognition of “community” pathogens, indicating their growing resistance to treatments and the substantial burden they pose, particularly in LMIC: 🔸 Salmonella Typhi fluoroquinolone-resistant is placed very high among the community pathogens 🔸  non-typhoidal Salmonella fluoroquinolone-resistant was also moved up and is included in the high-priority category 🔸 Shigella spp. fluoroquinolone-resistant are other notable community pathogens that were ranked higher overall in the BPPL 2024 update, moving from “medium” to “high” priority. 🔸 MDR N. gonorrhoeae (including FQ-R and 3G cephalosporin-R strains) has also remained in the high priority Medium-priority group includes: 🔸 Group A and B Streptococci 🔸 Streptococcus pneumoniae 🔸 Haemophilus influenzae 🖇 The WHO Press Release: https://rb.gy/ns05zu 🔗 Please read the full report here: https://lnkd.in/dJSKZNfb ☀ Congratulations to my fantastic team at WHO for this excellent effort to contribute to advance global public health! #AliCameron Hatim Sati

The misuse & overuse of antimicrobial drugs, including antibiotics, is causing antimicrobial resistance. This means antibiotics become less effective against infections. Learn more from the World Health Organization about this serious threat to global health: https://lnkd.in/eDZGbpDR